Skip to main content
BoF Logo

The Business of Fashion

Agenda-setting intelligence, analysis and advice for the global fashion community.

Galderma Sales Top $1 Billion, Led by Injectables

The public company reported strong sales, as demand for its dermatological skincare and injectable products surged.
Cetaphil products
Cetaphil maker Galderma is seeing strong growth. (Shutterstock)

Galderma, the Swiss cosmetic skincare and medical company, reported net sales growth of 12.4 percent to $1 billion in its first-quarter results announced today.

Known for brands such as Cetaphil and Differin as well as cosmetic aesthetic products such as Dysport, Sculptra and Restylane, Galderma went public in March. It initially raised $2.6 billion, with its stock surging 18 percent on its first day of trading.

Year-on-year growth was reported in all categories, with a 19.3 percent increase in injectables, 8.4 percent spike in dermatological skincare and 4 percent growth for therapeutic products.

Within the injectables category, sales of neuromodulators (such as Botox alternative Dysport), were $263 million, up 20.4 percent, while fillers and biostimulators were $248 million, up 18.2 percent. The growth was mainly led by volume, as demand for so-called “tweakments”, or minimally invasive procedures continues to rise. Dermatological skincare sales, led by affordable brand Cetaphil, were $351 million, with global expansion in Asia, as well as marketing efforts tied to New York Fashion Week and the Super Bowl were noted as growth drivers.

ADVERTISEMENT

Galderma has confirmed its full-year guidance of 7-10 percent net sales growth year-on-year.

Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day’s most important beauty and wellness news and analysis.

Learn more:

Lashes, Brows, Botox: How Much is Too Much?

Not longer the domain of the elite, lash extensions, brow treatments, injectables and more have become part of mainstream consumers’ beauty maintenance routines. But online backlash is brewing against growing pressure for elaborate upkeep.

© 2024 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

More from Beauty
Analysis and advice on the fast-evolving beauty business.

Why Everyone Is in Love With Blush Again

Once thought of as a somewhat dowdy, staid product, younger consumers are now embracing blush, wearing multiple products, formulas and shades as part of their daily look.


The Important Message Behind ‘So Many Dicks’

A genius marketing campaign from E.l.f. Beauty this week emphasised how diversity, equity and inclusion efforts can be done at the highest levels — and what the barriers are to making substantial progress.


view more

Subscribe to the BoF Daily Digest

The essential daily round-up of fashion news, analysis, and breaking news alerts.

The Business of Fashion

Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON
The Business of Beauty Global Forum
© 2024 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions, Privacy Policy, Cookie Policy and Accessibility Statement.
The Business of Beauty Global Forum